[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Institut Mutualiste Montsouris\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":130},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,49,84,106],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100591607","supra-inguinal-fascia-iliaca-block-as-rescue-analgesia-following-total-hip-arthroplasty-100591607",false,"NCT06982625","Supra Inguinal Fascia Iliaca Block as Rescue Analgesia Following Total Hip Arthroplasty","SOSBIFSI","Inclusion Criteria:\n\n* patient scheduled for a primary total hip arthroplasty under general anesthesia,\n* written informed consent.\n\nNon inclusion criteria:\n\n* contra indication to ropivacaine\n* vulnerable person\n\nExclusion Criteria:\n\n* per-operative complication making wheight-bearing and walking contra-indicated.\n* patient without significant pain post-operatively.","ALL","18 Years",{"count":19,"type":20},310,"ESTIMATED","INTERVENTIONAL",[23],"NA","Hip replacement surgery is one of the most commonly performed surgical procedures in France, with approximately 150,000 procedures per year. Postoperative recovery has significantly improved in recent years, enabling faster rehabilitation.\n\nAlthough generally considered moderately painful, hip replacement surgery can, in some difficult-to-predict cases, lead to severe postoperative pain, requiring high doses of morphine, which may cause side effects and delay recovery.\n\nIn other surgical procedures, regional anesthesia (nerve blocks) has been successfully used for pain relief. However, its effectiveness after hip replacement surgery has not yet been fully proven.\n\nA recent regional anesthesia technique-the Supra-Inguinal Fascia Iliaca Block (SIFIB)-which numbs a significant portion of the nerves around the hip, has recently been developed.\n\nWhen performed in all patients undergoing hip arthroplasty, the benefit of this technique could not be demonstrated. In addition, this technique may lead to transcient muscle blockade, wich also can delay recovery.\n\nIn order to limit the use of nerve blocks to painful patients, we designed this study where the nerve block is performed only in patients experiencing significant paint after surgery.\n\nIn conclusion, this study aims to assess the benefits of performing a rescue SIFIB in the recovery room for patients who experience significant postoperative pain after hip replacement surgery. The evaluation will focus on pain relief and ability to walk.\n\nNo new treatment is being tested. The technique uses a commonly administered local anesthetic to numb the nerves.",[26,27,28],"Hip Arthroplasty, Total","Post Operative Pain, Acute","Nerve Block",[30,31,32,33,34,35,36],"Total hip arthroplasty","Regional anesthesia","Nerve blocks","Supra-inguinal fascia iliaca block","Enhanced recovery after surgery","Acute post-operative pain","Rescue analgesia","RECRUITING","2025-09-22",{"date":40,"type":41},"2025-09-25","ACTUAL",{"date":38,"type":41},{"date":44,"type":20},"2027-12-31",{"name":46,"class":47},"Institut Mutualiste Montsouris","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":57,"minAge":4,"maxAge":4,"enrollmentInfo":58,"targetDuration":60,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":4},"100575425","focal-therapy-in-localized-prostate-cancer-a-prospective-registry-100575425","NCT06772116","Focal Therapy in Localized Prostate Cancer: a Prospective Registry","Jupiter Registry: Prospective Registry for Patients Undergoing Focal Therapy for Localized Prostate Cancer","JR","Inclusion Criteria:\n\n* Patients with intermediate risk PCa based on EAU risk groups with life expectancy \\> 10 years\n* Prior targeted + systematic biopsy using US-MRI fusion technique\n* Primary focal treatment (targeted or partial gland ablation) of PCa lesion(s) detected on mpMRI, where PCa ISUP 2 or 3 has been identified. PCa ISUP 1 outside the treatment areas is acceptable, regardless of volume.\n* Focal treatment was performed using one of the following energies: high-intensity focused ultrasound (HIFU), cryotherapy (CRYO), brachytherapy (BT), irreversible electroporation (IRE), focal laser ablation (FLA), vascular-targeted Photodynamic (VTP) and radiofrequency ablation (RFA) according to the country rules, approvals, and regulations of each country in which they are applied. The registry cannot be used as a clinical trial or post-marketing surveillance study of the technologies applied.\n* Free, informed and written consent\n\nExclusion Criteria:\n\n* Patients with intermediate risk treated with focal therapy without a previous targeted + systematic prostate biopsy with US-MRI fusion technique.\n* Primary focal treatment of PCa ISUP 2 or 3 in areas of prostate without evidence of lesions on MRI (MRI-invisible prostate cancer)\n* Patients with histological diagnosis of PCa with ISUP \\> 1 outside the areas of treatment\n* Primary whole gland treatments using ablative energy HIFU, cryotherapy, IRE, FLA, VTP and\u002For RFA\n* Primary subtotal\u002Ftotal treatments using ablative energy HIFU, cryotherapy, IRE, FLA, VTP and\u002For RFA\n* Life expectancy \\\u003C10 years\n* Previous treatment of PCa (excluded a period of Active Surveillance)\n* High risk PCa based on EAU risk groups.\n* Locally advanced PCa\n* Metastatic hormone-sensitive prostate cancer (mHSPC)\n* Metastatic castration-resistant prostate cancer (mCRPC)\n* Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)","MALE",{"count":59,"type":20},1000,"5 Years","OBSERVATIONAL","The principal aim of the registry is to collect data on focal therapy (FT) for the treatment of intermediate-risk prostate cancer across Europe. Data will be gathered on cancer absence following treatment, survival rates, and the absence of disease failure or progression. Information will be collected from as many centers as possible over the next 5 years to enhance understanding of when focal therapy should be used, which energy types are most effective, and how patients respond to treatment, including its side effects and impact on quality of life.\n\nThis Europe-wide data collection will contribute to improving care by informing the development of enhanced national and international guidelines for prostate cancer treatment with focal therapy.",[64,65],"Prostate","Prostate Cancer",[67,68,69,70,71,72,73,74],"Focal Therapy","HIFU","Cryotherapy","FLA","Focal Brachytherapy","IRE","VTP","RFA","NOT_YET_RECRUITING","2025-01-08",{"date":78,"type":41},"2025-01-13",{"date":80,"type":20},"2025-02",{"date":82,"type":20},"2032-02",{"name":46,"class":47},{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":21,"phases":94,"briefSummary":95,"conditions":96,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":48},"100565828","comparison-of-3-rf-delivery-modes-of-the-qdot-catheter-for-paroxymal-atrial-fibrillation-af-ablation-100565828","NCT06647251","Comparison of 3 RF Delivery Modes of the QDOT Catheter for Paroxymal Atrial Fibrillation (AF) Ablation","Comparison of 3 RF Delivery Modes of the QDOT Catheter for Paroxymal AF Ablation: a Prospective Study","QDOT","Inclusion Criteria:\n\n* Patient aged 18 or over\n* First atrial fibrillation ablation\n* Paroxysmal atrial fibillation defined as atrial fibrillation lasting less than 48 hours\n* Early atrial fibrillation defined as atrial fibrillation lastiing between 7 days and 3 months\n* At least one episode of atrial fibrillation in the year preceding study entry\n* Patient affiliated to a health insurance\n\nExclusion Criteria:\n\n* History of atrial fibrillation ablation (surgery or catheter)\n* Documented left atrial thrombus\n* Left atrial (LA) diameter \\> 60mm \u002F LA area \\> 35cm2 \u002F Left atrial volulme index (LAVI) \\> 45ml\u002Fm2\n* N\u002FSTEMI replacement or angioplasty or valve within 3 months prior to registration\n* Any contraindication mentioned in the instructions for use of the QDOT MICRO™ bidirectional navigation catheter\n* Patient unable to understand study information\n* Patient deprived of liberty by judicial or administrative decision",{"count":93,"type":20},90,[23],"Pulmonary vein isolation is the main treatment of paroxysmal and persistent atrial fibrillation.\n\nThe aim of our study is to prospectively compare the efficacy and safety of the 3 options of radiofrequency delivery with QDOT Micro™, with systematic use of catheter stabilization tools and tighter lesions",[97],"Atrial Fibrillation","2024-10-16",{"date":100,"type":41},"2024-10-17",{"date":102,"type":20},"2024-10",{"date":104,"type":20},"2028-10",{"name":46,"class":47},{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":48},"100500718","fast-track-cardiovascular-assessment-for-suspicion-of-cardiovascular-events-on-immunecheckpoint-inhibitors-100500718","NCT05799898","Fast-Track Cardiovascular Assessment for Suspicion of Cardiovascular Events on Immunecheckpoint Inhibitors","Fast-Track Cardiovascular Assessment for Suspicion of Cardiovascular Events on Immunecheckpoint Inhibitors: Prospective Cohort Study.","FAST-TRACK","Inclusion Criteria:\n\n* all patient referred to the cardio oncology unit for suspected immune related cardiovascular complication on immune checkpoint inhibitors\n\nExclusion Criteria:\n\n* none",{"count":115,"type":20},200,"Prospective study cohort on patients addressed for suspected cardiovascular event on immune checkpoint inchibitors.\n\nLongitudinal prospective single center cohort. Inclusion criteria: all patient willing to particiupate seen in the cardio-oncology unit at our institution for the suspicion of heart failure, atherosclerosis related event, Tako Tsubo, arrhymias, pericarditis, myocarditis on antiPD1, antiPDL1, or antiCTLA4 immune checkpoint inhibitors.\n\nDescription of patients characteristics, investigations, diagnosis after multidisciplinary meeting, outcomes.",[118,119,120,121],"Cancer","Immune Checkpoint Inhibitor","Cardiovascular Complication","Immune-related Adverse Event","2023-03-23",{"date":124,"type":41},"2023-04-05",{"date":126,"type":41},"2022-03-01",{"date":128,"type":20},"2030-01-01",{"name":46,"class":47},""]